STOCK TITAN

4,194-share notice: EXPO (NASDAQ: EXPO) affiliate plans option exercise sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

EXPO affiliate submitted a Form 144 notice to sell 4,194 shares of Common Stock via exercise of stock options on 05/15/2026. The filing also lists 10b5-1 sales by Catherine Corrigan in the prior three months: 3,909, 3,912, and 3,920 shares with gross proceeds reported.

Positive

  • None.

Negative

  • None.

Insights

Routine affiliate notice of option exercise and proposed resale under Form 144.

The filing records an exercise of stock options and a proposed sale of 4,194 shares on 05/15/2026. Form 144 is a regulatory notice required when an affiliate intends to sell restricted or control securities.

Prior 10b5-1 sales by Catherine Corrigan on 02/17/2026, 03/16/2026, and 04/15/2026 are listed with gross proceeds; cash treatment is shown for the exercise. Transaction timing and final sale mechanics depend on market execution and plan terms.

Shares proposed for sale 4,194 shares Exercise of stock options on 05/15/2026
10b5-1 sale (Apr 15, 2026) 3,909 shares 10b5-1 sale by Catherine Corrigan on 04/15/2026
Gross proceeds (Apr 15, 2026) $264,625.23 Proceeds reported for 04/15/2026 10b5-1 sale
10b5-1 sale (Mar 16, 2026) 3,912 shares 10b5-1 sale by Catherine Corrigan on 03/16/2026
Gross proceeds (Mar 16, 2026) $264,013.84 Proceeds reported for 03/16/2026 10b5-1 sale
10b5-1 sale (Feb 17, 2026) 3,920 shares 10b5-1 sale by Catherine Corrigan on 02/17/2026
Gross proceeds (Feb 17, 2026) $263,239.62 Proceeds reported for 02/17/2026 10b5-1 sale
Form 144 regulatory
"Form 144 notice to sell 4,194 shares via exercise of stock options"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
10b5-1 regulatory
"10b5-1 Sales for CATHERINE CORRIGAN listed with dates and share counts"
A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.
Exercise of Stock Options financial
"Securities To Be Sold | 05/15/2026 | Exercise of Stock Options"

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does EXPO's Form 144 filing report?

The filing reports a proposed sale of 4,194 shares of Common Stock via an exercise of stock options scheduled for 05/15/2026. It is a regulatory notice of an affiliate sale.

Who conducted recent 10b5-1 sales mentioned in the filing?

The filing lists three 10b5-1 sales by Catherine Corrigan on 02/17/2026, 03/16/2026, and 04/15/2026, each showing share counts and gross proceeds.

How many shares were sold in the prior 10b5-1 transactions?

The prior 10b5-1 transactions show sales of 3,920, 3,912, and 3,909 shares on the listed dates, with associated gross proceeds reported in the filing.

What proceeds are reported for the recent 10b5-1 sales?

The filing shows gross proceeds of $263,239.62, $264,013.84, and $264,625.23 for the three listed 10b5-1 sales by Catherine Corrigan.